“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: Immix Biopharma
Immix Biopharma’s lead asset, IMX-110, is being investigated in a Phase Ib/IIa study for the treatment of soft tissue sarcoma and a Phase Ib trial in advanced solid tumors in combination with the ICI tislelizumab. Immix also has a pre-clinical pipeline based on the TSTx technology.
Immix Biopharma — 1 video in collection
Immix Biopharma is developing a new class of tissue-specific therapeutics (TSTx) targeting oncology and immune-dysregulated disease. In Q422, the company’s lead clinical asset, IMX-110, is expected to begin a Phase IIa study for the treatment of soft tissue sarcoma and a Phase Ib trial in advanced solid tumours in combination with the ICI tislelizumab. The company also has a preclinical pipeline based on the TSTx technology. In this video, Immix Biopharma’s CEO, Dr Ilya Rachman, provides an overview of the company’s strategy and approach.
Get access to the very latest content matched to your personal investment style.
